How Antibodies Reach Commercial Scale for Diagnostic Tests
Whitepaper
Published: October 12, 2026
Brought to you by
Merck
Merck is a science and technology company operating across healthcare, life science and performance materials. Their tools, services and digital platform make research simpler and more exact, helping to deliver breakthroughs more quickly.
Credit: Merck.
Diagnostic immunoassays need antibodies with consistent performance across batches.
Assay developers draw on different skills at each stage, from immunogen design through cell line development to large-scale fermentation.
This whitepaper follows an antibody's path to full production and shows where a contract partner can take on one step or the whole process.
Download this whitepaper to learn:
- Where recombinant methods offer advantages in antibody yield, reproducibility, and specificity
- How buffer, pH, and salt screens can cut purification runs and consumable use
- Why optimized feeding and culture conditions can save time and make batch failures less likely
White Paper
Contract Antibody Development,
Manufacturing, Purification, and Cell
Banking for Immunoassays
How partnering with an antibody production expert can improve your
assay, accelerate launch, and maintain your manufacturing.
Antibody development for
diagnostic immunoassays
Antibody-based disease biomarker detection powers
many of the diagnostic tests in use today. Despite its
venerable 40+ year history in diagnostics, antibody
development, scale-up and mass manufacturing
for assays remains a complex process with many
pitfalls and restarts. Part of the challenge is that the
skill sets needed for each of the three main steps:
Antibody Development, scale up, and manufacturing
are considerable and different, requiring the assay
commercialization team to master diverse technologies
and techniques. Further, the commercialization team
is faced with decisions on outsourcing parts of the
process or investing in in-house expertise and capital
expenditures. Often, when the immunoassay project
has narrow performance specifications or tight launch
deadlines, seeking out experienced development
support is prudent. Fortunately, advanced technologies
in the hands of antibody and assay development
experts are improving the immunodiagnostic process.
In this paper, we take you through key steps in the
modern antibody development process for diagnostic
assays using advanced technology. By simplifying
cell line development, scale up and antibody
manufacturing with a partner who understands
diagnostic immunoassay development we can
supplement your IVD capabilities and shorten your time
to commercialization.
Antibody & Immunoassay Development
The sensitivity, consistency, and reliability of
immunoassays, as well as their manufacturing cost,
is heavily dependent on the quality of the antibodies
used. Despite the use of antibodies to identify
disease antigens since the 1890’s, the production of
antibodies, from immunogen design to immunoglobulin
purification remains a formidable process requiring
significant expertise from the beginning. For many
antigen targets, care must be taken to design linear or
3D immunogens for optimal antibody avidity against
natural epitope structures.
Polyclonal & monoclonal
antibody development
Until the recent development of recombinant
technologies, the classical methods to produce
polyclonal and monoclonal antibodies relied on an
animal's immune response when exposed to a selected
antigen. For polyclonal antibodies, a given antigen
is introduced into an animal to elicit it's immune
response. The collected plasma will contain a blend of
antibodies produced from several clones. All antibodies
are directed toward the same antigen but will recognize
different epitopes. Monoclonal antibodies take this
process further by isolating a single B cell that is then
merged with a human myeloma cell line, to create a
hybridoma cell line, which will consistently produce
the exact same antibody using in vitro or in vivo
production vector.
The Life Science business of Merck
operates as MilliporeSigma in the
U.S. and Canada.
SLS_DX_WW_51628_Custom Antibody White Paper_MRK.indd 1 10/11/23 1:42 PM
2
Both techniques have challenges:
• Scalability: Milligram quantities are accessible, but
gram or kilogram amounts become difficult because
too many animals could be needed.
• Responsiveness: Both methods rely on immune
system response, which needs time. When a quick
turnaround is needed (i.e., for rapid development
of assays) this is not the best option for robust
antibody production.
• Biological variability: Lot-to-lot inconsistency for
polyclonals is common due to considerable variability
in each animals' immune response.
• Even monoclonals are not always 100%
monoclonal: The clone selection process is imperfect
science and can sometimes lead to multiple clone
selection, resulting in manufacturing of antibodies
able to recognize several epitopes. This can be a
problem when a high level of specificity is required
from the antibody.
• AG drift: Shift in antigen recognition after too many
clone cell culture productions could result in changes
to the antibody's specificity.
• Production efficiency: There are limitations in scale
but also in animal species.
• Animal welfare constraints: Polyclonal and
monoclonal production requires considerable animal
usage through animal immunization and subsequent
sera collection or the use of fetal bovine serum (FBS)
in cell culture media, respectively.
Recombinant antibody development
The emergence of recombinant protein technologies
has provided an efficient and sustainable approach
to antibody development. Although the approach
requires considerable expertise, from a technical
standpoint, recombinant antibodies production present
many advantages:
• Scalability: By scaling the size of a bioreactor,
antibody quantity requirements can be met
more easily.
• Efficiency: Optimizing the recombinant protein
expression system increases the cell line
production efficiency.
• Reproducibility: By controlling the genetic code it is
easier to ensure the antibody's consistency.
• Species flexibility: Antibodies can be created in
species that are not able to be used as a host in
traditional methods.
• 100% monoclonality: By engineering the DNA, there
is much tighter control of the antibody's specificity.
• Sustainability: Recombinant antibody production
utilizes an animal free media to produce large
quantities of antibodies for commercial applications.
Support from Us
Partnering with a comprehensive expert in antibody
design, development, and manufacturing is an
increasingly viable business decision in creating a firm
foundation for your immunoassay commercialization.
Merck has been providing the research and diagnostics
community with precision antibodies since the 1980’s.
With a 90K+ Product Portfolio and 400 new products
developed per year, their experienced and dedicated
R&D team has developed an extensive range of
custom antibody. In recent years, we have been using
Recombinant Antibody technology to create the next
generation of research antibodies and engineered
custom antibody development for commercial partners.
With dedicated ISO certified, GMP-guided IVD Antibody
Innovation Centers in Rocklin, CA, USA and Livingston,
Scotland we have the expertise to support your
antibody development at any stage.
SLS_DX_WW_51628_Custom Antibody White Paper_MRK.indd 2 10/11/23 1:42 PM
3
Scale-up / Engineering / Tech Transfer
The scale-up of antibody production needed for
commercial assays consists of several key steps, each
with their own technical considerations and required
expertise. The chosen cell line must be stabilized
for scale-up and long-term consistency, followed by
fermentation & purification optimization, and finally
transfer of the process to routine production.
Stable cell line generation
Converting an antibody producing B-Cell clone to a
stable cell line is critical for producing, consistent,
reliable supplies of antibodies for commercialization.
Ideally, stable cell line generation is achieved by
cloning the underlying genes coding for the antibody
heavy and light chains into robust, high yielding CHO
cell lines. The process includes first isolating the IgG
producing PBMC cells from a blood sample of the
unharmed animal. Then RTPCR and PCR are completed
to amplify the heavy chain and light chain. The
amplified DNA sequences are cloned into expression
vectors that are then introduced to the CHO expressing
cells. During this process, IgG can be produced and
tested transiently to confirm that the antibody is
preforming as expected.
Fermentation &
purification optimization
Scale-up of antibody production
requires the use of cell banking,
fermentation, and purification
processes. Robust cell banking
transfers the cell line to (preferably)
animal serum-free media and
then through development of pre seed stocks (PSS),
followed by master cell bank (MCB) and production cell
bank (PCB). The stable pre seed stock should undergo
adventitious virus testing and mycoplasma testing is
carried out at each stage of the cell line development.
Stability studies are completed on the cell banks to
ensure cell line stability and suitability for cell banking
and robust manufacturing.
Fermentation conditions for the new stable cell lines
can be optimized to identify ideal growth conditions
for higher yields. The use of small scale stirred tank
Reactors allow the ability to robustly optimize and test
our processes in a small-scale cost-effective manner
before scaling to provide large scale production.
Working out the culture inoculum and media conditions
in scale-up not only saves on reagent costs but
provides more consistent batches from the start.
Transfer to Production
At this stage, cell lines can be
scaled up from a 2 L Mobius
to a 200 L Mobius fermenter
at production scale. Once
fermentation conditions are
set, purification processes
are optimized to meet the
necessary purity requirements
for the project. Depending on
the antibody, purification can
be by any method depending
on the customer requirements. Examples include size
exclusion, ion exchange or, most commonly, affinity
purification. For affinity purification a range of different.
Different buffers, pH and salt concentrations are
screened and the binding conditions are optimized.
These optimization steps cannot be understated
because by optimizing the purification conditions the
number of runs required, and volume of consumables
can be reduced, thereby making the manufacturing
process more sustainable and cost effective.
Support from Us
For antibody scale-up assistance, your partner should
be not only technically competent but also have the
quality systems to support and validate the product
development. Our Livingston, Scotland facility has
extensive experience in developing, banking, scaling,
and manufacturing IVD antibodies for diagnostic
partners. Under ISO certifications 13485, ISO 9001,
and ISO 14001, the manufacturing team has access
to a large variety of different bio reactors ranging
from 2 L Mobius fermenters to 200 L single use
Mobius and stainless steel airlift fermenters. The site
also has the capability to manufacture antibodies
through continuous fermentation systems. Their
purification expertise (over 10 years) can reduce
optimization times and provides complete validation
and supporting documentation. Continuous process
improvement and innovation initiatives translates to
improved methodologies that save reagent resources,
reduce waste, improve sustainability, and lower costs
for customers.
SLS_DX_WW_51628_Custom Antibody White Paper_MRK.indd 3 10/11/23 1:42 PM
Optimization & Manufacturing
Process optimization from the beginning of a new
product or the introduction of a new cell line is a useful
tool and important step before the introduction of a
product to full scale manufacture. Inconsistency within
batches can lead to variability in product quality and
can result in unplanned batch failures, increases in
manufacturing time and an increase in cost due to the
need to remanufacture and reprocess the product.
Manufacturing optimization in vitro can lead the way
to consistent and reproducible processes and therefore
consistent product quality. Ideally, manufacturing
process optimization is performed for all new cell lines
for upstream and downstream processes.
Typical parameters that need optimization include:
• pH
• Dissolved oxygen tension
• Temperature
• Feeding strategy
• Agitation
• Media and feed components
For example, a critical step for developing a fedbatch
process is selecting an appropriate medium
and feed. Optimizing the feeding strategies of a cell
line can prevent nutrient limitation and limit the
production of toxic by-products. By optimizing each
cell line individually one can find the best in vitro
running parameters to increase the productivity on a
per cell line basis. Considering the generic cell culture
parameters listed can provide a process that minimizes
lot-to-lot inconsistency, potentially saving production
time/cost and reducing risk of failures.
Support from Us
At Livingston we strive to optimize all new cell lines
that come through our site using small scale in vitro
batches which can then be scaled up into large scale
manufacturing bioreactors in a GMP environment. Using
a range of design of experiment (DOE) techniques we
can optimize product quality and yield before scaling
up. Some of the DOE techniques we use on site are:
• Using multifactorial screening for important factors
such as pH and DOT, we can manipulate multiple
inputs to determine their effect on process/product
output and can reveal critical interactions that are
often missed when performing single or fractional
factorial experiments.
• Split plot designs can be integrated to look at
challenging factors to capture any significant effects
on productivity such as temperature or agitation.
• After deciding the important factors during the initial
screening designs a response surface design can then
be created for final process optimization.
Conclusions on Custom Antibody
Development & Manufacturing
Reliable, consistent, and robust antibody manufacturing
for tissue diagnostics or IVD assays requires diverse
expertise that may not all reside in-house. Whether
your outsourcing need is for just one step, or the
entire process, you have a partner available with
end-to-end capabilities and expertise. Our custom
antibody development service relies on collaboration
between our customer and multiple entities from
our side including R&D, Quality, Regulatory, Process
engineering, and Manufacturing. Contact us to discuss
your antibody development needs.
To place an order or receive technical assistance
In Europe, please call Customer Service:
France: 0825 045 645
Germany: 069 86798021
Italy: 848 845 645
Spain: 901 516 645 Option 1
Switzerland: 0848 645 645
United Kingdom: 0870 900 4645
For other countries across Europe, please call: +44 (0) 115 943 0840
Or visit: MerckMillipore.com/offices
For Technical Service visit: MerckMillipore.com/techservice
MerckMillipore.com
Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany
© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck and the vibrant M are trademarks of Merck
KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on
trademarks is available via publicly accessible resources.
MK_WP12877EN Ver. 1.0
51628
11/2023
SLS_DX_WW_51628_Custom Antibody White Paper_MRK.indd 4 10/11/23 1:42 PM
Sponsored by
Merck
Merck is a science and technology company operating across healthcare, life science and performance materials. Their tools, services and digital platform make research simpler and more exact, helping to deliver breakthroughs more quickly.
Download the Whitepaper for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version